TAYCA (4027) FY2027 Q1 Earnings Report

Quick View

Executive Summary

In FY2027 Q1, Teika achieved both double-digit revenue growth and cost efficiencies, resulting in higher revenue and profits. Revenue was ¥16.17B (¥13.68B in the same period of the previous year, YoY +18.2%), Operating Income was ¥1.31B (¥0.96B, YoY +36.4%), Ordinary Income was ¥1.74B (¥1.09B, YoY +59.1%), and Net Income was ¥1.24B (¥0.76B, YoY +63.8%). In addition to revenue growth, operating leverage from the lower SG&A ratio and the boost from non-operating income, including dividend income and foreign exchange gains, resulted in the profit growth rate significantly exceeding the revenue growth rate.

Factors Affecting Performance

【Revenue】Revenue increased 18.2% YoY to ¥16.17B, representing double-digit growth. By segment, the Electronic Materials and Chemicals Business continued to deliver strong growth, with revenue of ¥7.22B (+28.7%), while the Medical and Piezoelectric-Related Business recorded revenue of ¥1.26B (+33.0%). The Functional Materials Business achieved steady but more modest growth of ¥7.40B (+8.0%). By revenue composition, Functional Materials accounted for approximately 46% and Electronic Materials and Chemicals approximately 45%, making these two businesses the core segments.

【Profit and Loss】Operating Income increased 36.4% YoY to ¥1.31B, and the Operating Income margin improved to 8.1% from 7.0% in the previous year. Against a gross margin of 19.4%, the SG&A ratio declined to 11.3%, with cost efficiencies contributing to profit growth. Ordinary Income increased 59.1% YoY to ¥1.74B, with ¥0.48B in non-operating income—including ¥0.30B in dividend income and ¥0.08B in foreign exchange gains—boosting income at the ordinary income level. Net Income increased 63.8% YoY to ¥1.24B, while the impact of ¥0.02B in extraordinary losses (losses on disposal of fixed assets) was minor. The company achieved higher revenue and profits, with non-operating income adding to improvements at the operating level.

Segment Analysis

The largest segment by segment profit was the Electronic Materials and Chemicals Business, with profit of ¥0.75B (10.4% margin, YoY +32.5%), accounting for more than half of total company profit. The Medical and Piezoelectric-Related Business generated profit of ¥0.22B (17.1% margin), the highest margin company-wide, and expanded sharply by YoY +300.0%. The Functional Materials Business generated profit of ¥0.28B (3.8% margin), relatively low profitability, indicating room for improvement despite having the largest revenue scale. Other Businesses recorded profit of ¥0.06B (9.1% margin, YoY -3.4%), representing a modest decline. The rising contribution of the high-margin businesses—Electronic Materials and Chemicals and Medical and Piezoelectric-Related—drove the improvement in the company-wide Operating Income margin to 8.1%.

Key Financial Metrics

【Profitability】The Operating Income margin improved to 8.1% from 7.0% in the previous year, while the Net Income margin expanded to 7.7% from 5.5%. The gross margin was 19.4%, and the decline in the SG&A ratio to 11.3% supported profit growth at the operating level.【Cash Quality】The company held ¥10.45B in cash and deposits and ¥17.78B in investment securities, reflecting a conservative asset composition. Working capital was substantial, with inventories of ¥9.66B and accounts receivable of ¥18.02B.【Investment Efficiency】ROE was 2.0%; given the high capital base reflected in an Equity Ratio of 68.5%, capital efficiency remained low, partly due to the low total asset turnover ratio.【Financial Soundness】The Equity Ratio was 68.5%, while long-term borrowings were ¥4.80B, indicating a limited debt burden and a stable financial foundation.

Cash Flow Analysis

As the cash flow statement has not been disclosed, funding trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥10.45B, slightly below the ¥10.85B level in the same period of the previous year. Accounts receivable were ¥18.02B (¥16.87B in the previous year), while inventories were ¥9.66B (¥9.79B in the previous year), indicating an upward trend in trade receivables accompanying revenue growth. Accounts payable increased to ¥7.80B (¥6.07B in the previous year, +28.6%), reflecting the expansion of procurement and production activities. Given the levels of trade receivables and inventories, a certain amount of funds remains tied up in working capital. Monitoring funding efficiency during the revenue growth phase will therefore be an important focus going forward.

Quality of Earnings

Against Operating Income of ¥1.31B, which indicates the earning power of the core business, ¥0.48B in non-operating income (¥0.30B in dividend income and ¥0.08B in foreign exchange gains) boosted Ordinary Income. This represented approximately 3.0% of revenue. Extraordinary items consisted solely of ¥0.02B in extraordinary losses (losses on disposal of fixed assets), with a minor impact on Net Income; the contribution from one-off factors was limited. The difference between Ordinary Income of ¥1.74B and Net Income of ¥1.24B was primarily attributable to the recording of ¥0.47B in income taxes and other taxes, resulting in an effective tax rate of approximately 27%, a standard level. Comprehensive Income was ¥1.38B, slightly exceeding Net Income of ¥1.24B, mainly due to a ¥0.16B increase in valuation difference on investment securities. The gap between Net Income and Comprehensive Income was limited, and no factor was identified that would materially impair earnings quality.

Earnings Forecast and Guidance

Progress against the full-year forecasts—Revenue of ¥59.50B, Operating Income of ¥2.50B, and Ordinary Income of ¥2.90B—was 27.2%, 52.2%, and 59.9%, respectively, in Q1, substantially ahead of the simple 25% benchmark. In particular, the high progress rates for Operating Income and Ordinary Income reflect SG&A efficiencies and contributions from non-operating income (dividends and foreign exchange), indicating that performance is ahead of schedule against the full-year plan. Given that the earnings forecast was revised during the current quarter, continued monitoring of progress toward the second half remains important.

Shareholder Returns

The full-year dividend forecast is ¥80 (changed from the previous year's actual dividend of ¥20), resulting in a Payout Ratio of approximately 101% against the company's forecast EPS of ¥78.84. As the Payout Ratio is effectively above EPS, achieving the full-year Net Income plan will be a prerequisite for securing the source of dividend payments, although the dividend forecast itself has not been revised. No share buyback was confirmed; however, treasury shares decreased from ¥1.197B in the same period of the previous year to ¥0.426B, indicating movements such as the disposal or cancellation of treasury shares as part of capital policy.

Risk Factors

1. Working capital tied-up: Accounts receivable of ¥18.02B and inventories of ¥9.66B have expanded along with revenue growth, creating a structure in which funds are tied up in these assets. If the revenue growth trend continues, improving collection and inventory management efficiency will be a funding efficiency challenge.

2. Dependence on non-operating income: Of Ordinary Income of ¥1.74B, ¥0.48B consisted of non-operating income (¥0.30B in dividend income and ¥0.08B in foreign exchange gains), items that may fluctuate with market conditions, including equity markets and foreign exchange rates.

3. Segment mix concentration: The Functional Materials Business, which accounts for approximately 46% of revenue, has a profit margin of 3.8%, below the company-wide average. Dependence on the strong growth of the Electronic Materials and Chemicals Business and the Medical and Piezoelectric-Related Business is increasing.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

The Operating Income margin was slightly below the industry median, while the Net Income margin exceeded the median, indicating a relatively efficient level in terms of non-operating income and tax burden.

Growth and Capital Efficiency

The revenue growth rate was substantially above the industry median, positioning the company among the high-growth companies in the industry.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. In addition to higher revenue and profits, operating leverage resulting from the lower SG&A ratio improved the Operating Income margin to 8.1% from 7.0% in the previous year. Growth in the high-margin Medical and Piezoelectric-Related Business and Electronic Materials and Chemicals Business drove the improvement in the company-wide margin.

2. Full-year progress was high, at 52.2% for Operating Income and 68.1% for Net Income, indicating that performance is ahead of schedule, including contributions from non-operating income (dividends and foreign exchange). As non-operating factors may fluctuate depending on market conditions, the quality of full-year earnings will focus on the accumulation of operating performance going forward.

3. The dividend forecast of ¥80 represents a Payout Ratio of approximately 101% against the company's forecast EPS of ¥78.84, making continued achievement of the full-year Net Income plan a prerequisite. The expansion of working capital accompanying increases in accounts receivable and inventories is also a subject for monitoring in terms of funding efficiency.

Theoretical Stock Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly available data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market stock price or a recommendation of any specific investment action.

Sensitivity: ¥2,197–¥2,317 at ±1% for the cost of equity, and ¥2,242–¥2,264 at ±0.1 for ω.

Notes:

• Because Net Income progress against the full-year forecast is 68%, exceeding the standard 25%, forecast EPS has been adjusted upward within an upper limit of +10% (because companies ahead of schedule tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated at a somewhat high level.

(Calculation model: Residual income model / Interest rate reference month: 2026-07 / This value is not a forecast or guarantee of the future stock price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Teika delivered a strong FY2027 Q1 earnings result, with profit growth materially outpacing sales growth. Revenue rose 18.2% year on year to ¥16.17bn. Operating income increased 36.4% to ¥1.31bn. Ordinary income increased 59.1% to ¥1.74bn, and profit attributable to owners rose 63.6% to ¥1.23bn. The operating margin expanded by approximately 109bp to 8.1% from 7.0% a year earlier. Gross margin was broadly stable at 19.4%, improving marginally by around 3bp. The principal source of operating-margin expansion was SG&A leverage, as the SG&A-to-sales ratio declined to 11.3% from 12.4%, a reduction of roughly 105bp. Electronic Materials & Chemicals was the largest contributor to segment profit and therefore remains the core business on an operating-income basis. Medical & Piezoelectric-related operations delivered the strongest growth rate, with segment profit quadrupling year on year. Functional Materials sales increased, but segment profit grew only modestly, indicating modest margin pressure in the group’s legacy pigment and surface-treatment operations. Earnings above the operating line also benefited from ¥305m of dividend income and ¥80m of foreign-exchange gains. Consequently, ordinary-income growth exceeded operating-income growth, making part of the net-profit acceleration dependent on investment income and foreign-exchange effects rather than solely on core operations. The effective tax rate was 27.5%, resulting in a normal tax burden factor of 0.715. The balance sheet remains conservatively capitalized, with a current ratio of 269.3%, net cash relative to short-term borrowings, and debt-to-equity of 0.46x. However, working-capital efficiency requires close attention, as quality alerts identify elevated receivable days, inventory days and a long cash conversion cycle. The full-year revised forecast implies that Q1 operating-income progress is already 52.2%, substantially above the conventional 25% first-quarter benchmark. This creates upside potential if momentum persists, but also means the revised guidance appears to embed either meaningful second-half normalization or conservatism. The forecast DPS of ¥80 exceeds forecast EPS of ¥78.84, indicating a projected dividend-only payout ratio above 100% and elevating the importance of future cash generation and capital-allocation discipline.

Profitability Analysis

Annualized DuPont ROE is 8.0%, comprising a 7.6% net profit margin, 0.719x annualized asset turnover and 1.46x financial leverage. The company’s return profile is driven primarily by solid margins and moderate leverage rather than exceptionally high asset utilization. Financial leverage is conservative and is not being used aggressively to enhance shareholder returns. The largest year-on-year improvement in reported profitability was operating leverage: revenue rose 18.2%, while SG&A increased only 8.2% to ¥1.84bn. This reduced the SG&A ratio by about 105bp and lifted operating margin to 8.1%. Gross profit increased 18.4% to ¥3.14bn, essentially in line with sales growth, so gross-margin improvement was not the central driver of earnings expansion. The 19.4% gross margin remains marginally below the 20% quality-alert threshold, leaving the business sensitive to raw-material, energy and product-mix changes. The five-factor framework shows an interest burden of 1.312 because non-operating income more than offset interest expense; this supports pre-tax profit but is not equivalent to a stronger operating EBIT margin. Interest expense was only ¥45m, and interest coverage was a very strong 29.0x. Dividend income of ¥305m represented 23.4% of operating income, while FX gains added ¥80m, so ordinary income contains a meaningful contribution from financial and investment-related income. The ¥24m loss on disposal of fixed assets was small, at about 2.0% of profit attributable to owners, and does not materially weaken earnings quality. The gap between ordinary income of ¥1.74bn and profit attributable to owners of ¥1.23bn was mainly explained by ¥471m of income tax expense and the small fixed-asset disposal loss. Segment performance was led by Electronic Materials & Chemicals, which generated ¥7.22bn of revenue, up 28.7% year on year, and ¥750m of segment profit, up 32.5%; its segment margin improved to 10.4% from 10.1%. Medical & Piezoelectric-related revenue increased 33.0% to ¥1.26bn and segment profit rose to ¥216m from ¥54m, lifting margin to 17.1% from 5.7%. Functional Materials revenue rose 8.0% to ¥7.40bn, but segment profit increased only 3.3% to ¥283m, reducing margin to 3.8% from 4.0%. Other businesses recorded revenue of ¥625m, up 5.4%, while profit declined 3.4% to ¥57m and margin fell to 9.1%.

Growth Assessment

Top-line growth was broad-based across the three reported operating segments, but the composition of growth favored higher-margin businesses. Electronic Materials & Chemicals added ¥1.61bn of revenue year on year and accounted for the largest absolute increase in segment profit, at ¥184m. Medical & Piezoelectric-related operations added ¥313m of revenue and ¥162m of segment profit, making it the most powerful incremental-margin contributor. Functional Materials added ¥548m in sales but only ¥9m in profit, suggesting that pricing, input costs or product mix limited conversion of growth into earnings. The segment reorganization effective in FY2027 Q1 separates Medical & Piezoelectric-related operations, improving visibility into the company’s identified growth businesses under the MOVING-10 STAGE 3 plan. Consolidated gross profit growth remained aligned with revenue growth, meaning that sustained profit expansion depends on continued SG&A discipline and favorable segment mix rather than broad gross-margin expansion. The revised full-year forecast calls for sales of ¥59.50bn, operating income of ¥2.50bn, ordinary income of ¥2.90bn and profit attributable to owners of ¥1.80bn. Q1 progress against this forecast is 27.2% for sales, 52.2% for operating income, 59.9% for ordinary income and 68.1% for profit attributable to owners. Sales progress is close to the standard 25% first-quarter pace, while operating-profit progress exceeds that pace by 27.2 percentage points. Ordinary-income progress exceeds the benchmark by 34.9 percentage points, supported by dividend income and FX gains. Net-income progress exceeds the benchmark by 43.1 percentage points. The substantial front-loading relative to revised guidance makes the sustainability of Q1 margins, investment income and currency gains key determinants of the full-year outcome. For a specialty chemical and electronic-materials manufacturer, demand cyclicality in electronics-related materials and fluctuations in titanium dioxide and chemical-input pricing remain important determinants of growth durability.

Financial Health

Liquidity is strong, with current assets of ¥49.34bn against current liabilities of ¥18.32bn, producing a current ratio of 269.3%. The quick ratio of 216.6% also indicates that liquidity is not dependent on selling inventories. Working capital was ¥31.02bn. Cash and deposits of ¥10.45bn covered short-term borrowings of ¥6.48bn by 1.61x. Total interest-bearing debt was ¥11.27bn, equivalent to a conservative debt-to-equity ratio of 0.46x, while debt-to-capital was 15.5%. Total liabilities represented 31.5% of total assets, leaving a substantial equity base of ¥61.63bn. Interest coverage of 29.0x indicates ample capacity to service reported interest costs. Long-term loans declined 17.4% year on year to ¥4.80bn, reinforcing the conservative solvency profile. The short-term debt ratio is nevertheless elevated at 57.5%, triggering the refinancing-risk alert because more than half of interest-bearing debt matures or is structured as short-term funding. This maturity concentration is manageable under current liquidity conditions, given cash exceeds short-term debt, but it leaves the company exposed to refinancing costs and bank-credit conditions if liquidity were required for operations or investment. Trade payables increased 28.6% year on year to ¥7.80bn, outpacing the 18.2% increase in revenue. This expansion provides short-term operating funding, but it should be monitored alongside the company’s longer receivable and inventory cycle. Treasury stock moved from negative ¥1.20bn to negative ¥0.43bn, a ¥0.77bn reduction in the treasury-stock deduction, increasing equity relative to the prior-year balance-sheet presentation. Investment securities totaled ¥17.78bn, or 19.8% of total assets, and associated dividend income is a meaningful contributor to ordinary earnings; this creates sensitivity to investee distributions and market valuations. Goodwill was only ¥593m, equal to 1.0% of equity and 0.7% of assets, while intangible assets were 0.9% of assets, indicating minimal M&A-related balance-sheet dependence and low goodwill impairment risk.

Notable B/S Changes

Accounts payable: +¥1.73bn (+28.6%) to ¥7.80bn - supplier financing increased faster than revenue growth, partially offsetting working-capital needs but requiring monitoring alongside high DSO and inventory-day alerts. Treasury stock: ¥0.77bn reduction in the negative treasury-stock balance, from -¥1.20bn to -¥0.43bn - the smaller equity deduction supported reported equity, which increased to ¥61.63bn. Long-term loans: -¥1.01bn (-17.4%) to ¥4.80bn - deleveraging improved long-term solvency, though 57.5% of interest-bearing debt remains short-term. Trade receivables: +¥1.16bn (+6.9%) to ¥18.02bn - receivables remain a substantial 20.0% of total assets and are relevant to the 102-day DSO quality alert. Investment securities: +¥0.22bn (+1.3%) to ¥17.78bn, representing 19.8% of total assets - the portfolio provides dividend income but maintains exposure to investee distributions and market-value movements.

Cash Flow Quality

Working-capital quality is the principal cash-conversion issue identified by the available operating data. Quality alerts flag receivable days of 102 days, which is above the 60-day warning threshold and implies relatively slow conversion of credit sales into cash. The same alerts identify inventory days of 135 days and a cash conversion cycle of 182 days, both materially above the relevant 90-day and 120-day warning thresholds. A separate inventory alert indicates 68 days against a 60-day benchmark; under either alert methodology, inventory efficiency is identified as an issue requiring monitoring. High receivable and inventory duration can increase funding needs during revenue growth and can amplify downside risk if customer demand weakens. Trade receivables were ¥18.02bn, equivalent to 20.0% of total assets, while inventories were ¥9.66bn, or 10.7% of total assets. Finished goods were ¥9.66bn, raw materials ¥6.88bn and work in process ¥2.69bn under the reported manufacturing classifications. Accounts payable increased to ¥7.80bn from ¥6.07bn a year earlier, which partially offsets working-capital investment but may not be a durable source of cash if supplier-payment terms normalize. The combination of high DSO, elevated inventory days and increasing payables is a working-capital pattern that warrants scrutiny for the timing of cash realization relative to reported earnings. The strong liquidity position mitigates immediate funding pressure, but cash conversion should be assessed against the pace of Electronic Materials & Chemicals and Medical & Piezoelectric-related growth.

Dividend Sustainability

The full-year forecast specifies DPS of ¥80 and forecast EPS of ¥78.84. This implies a forecast dividend-only payout ratio of approximately 101.5%. A payout ratio above 100% means the planned dividend exceeds forecast annual earnings per share. Retained earnings were substantial at ¥348.60bn, providing balance-sheet capacity to support shareholder distributions in the near term. The company also had ¥10.45bn of cash and deposits and a conservative debt-to-equity ratio of 0.46x. However, the elevated receivable days, inventory days and cash conversion cycle increase the importance of preserving operating cash generation while funding the dividend. Dividend income from investment securities supports ordinary profit, but it does not remove the need for internally generated cash flow to sustain recurring shareholder returns. No buyback amount is provided for the period, so the assessment is limited to the dividend-only payout ratio rather than a total return ratio. The sustainability of the ¥80 DPS will depend on whether the company can convert the strong Q1 earnings performance into full-year cash generation without a material build-up in receivables or inventory.

Risk Assessment

Business risks include Electronics-related demand risk: Electronic Materials & Chemicals is the core business by segment profit, contributing ¥750m, or 57.4% of consolidated operating income. A semiconductor, electronics or industrial-demand slowdown would therefore have a disproportionate effect on consolidated profit., Functional Materials margin risk: Functional Materials revenue rose 8.0%, but segment profit increased only 3.3%, reducing margin to 3.8%. The segment is exposed to titanium dioxide, zinc oxide, surface-treatment demand and chemical-input cost movements., Raw-material and energy-cost risk: The consolidated gross margin is only 19.4%, marginally below the 20% quality-alert threshold. Limited gross-margin headroom increases sensitivity to feedstock, energy and logistics cost inflation., Foreign-exchange risk: Q1 included ¥80m of FX gains, equal to 6.1% of operating income. Currency movements can reverse this contribution and add volatility to ordinary income., Investment-income risk: Dividend income was ¥305m, or 23.4% of operating income. A reduction in distributions from investees or portfolio changes would reduce ordinary profit even if operating performance is unchanged..

Financial risks include Refinancing risk: The 57.5% short-term debt ratio exceeds the 40% quality-alert threshold. Cash coverage of short-term debt is currently strong at 1.61x, but the maturity profile should be monitored as interest rates and bank funding conditions evolve., Receivables risk: The 102-day DSO quality alert exceeds the 60-day threshold. Extended collection periods increase credit exposure and may delay the conversion of strong reported sales into cash., Inventory risk: The 135-day inventory-days and 68-day inventory-days alerts both exceed their respective warning benchmarks. For a chemical and materials manufacturer, prolonged inventory holding raises risks of demand correction, price declines, obsolescence and working-capital absorption., Cash-conversion risk: The 182-day cash conversion cycle alert is well above the 120-day warning level. This can require greater reliance on cash balances, supplier credit or short-term borrowing during expansion., Portfolio valuation risk: Investment securities are ¥17.78bn, or 19.8% of assets, and unrealized valuation differences on securities are material within accumulated other comprehensive income. Market volatility can affect comprehensive income and equity..

Key concerns include The quality alerts on DSO, DIO and cash conversion cycle are the highest-priority operating-finance concerns because they can weaken cash realization during growth., Low gross margin is a medium-to-high priority concern because SG&A leverage, rather than gross-margin expansion, accounted for most of Q1 operating-margin improvement., The payout ratio implied by the revised full-year forecast is approximately 101.5%, requiring disciplined working-capital and balance-sheet management., Q1 operating-income progress of 52.2% versus the full-year forecast creates execution risk if segment margins, FX gains or dividend income normalize later in the year., The short-term debt ratio triggers a refinancing-risk alert, although strong current liquidity and low leverage materially reduce immediate balance-sheet stress..

Investment Implications

Key takeaways include Q1 operating income rose 36.4% to ¥1.31bn, outgrowing revenue by 18.2% through SG&A leverage and favorable segment mix., Electronic Materials & Chemicals is the core earnings engine, with ¥750m of segment profit and a 10.4% margin., Medical & Piezoelectric-related operations showed the strongest incremental profitability, with segment profit rising to ¥216m from ¥54m., Functional Materials remains strategically important by revenue but has a low 3.8% segment margin and limited profit conversion., Balance-sheet risk is low in aggregate, supported by a 269.3% current ratio, 0.46x D/E and 29.0x interest coverage., Working-capital efficiency and the sustainability of the forecast dividend are the principal financial issues to monitor..

Metrics to watch include Electronic Materials & Chemicals segment revenue growth and segment margin, Medical & Piezoelectric-related segment profit sustainability following its increase to ¥216m, Functional Materials margin, which declined to 3.8%, Gross margin relative to the 19.4% Q1 level, Receivable days, inventory days and cash conversion cycle, Short-term debt ratio and cash-to-short-term-debt coverage, Dividend income and FX effects within non-operating income, Progress against revised full-year operating-income guidance after Q1 progress reached 52.2%, Forecast dividend payout ratio, implied at approximately 101.5%.

Regarding relative positioning, Teika exhibits a stronger-than-average liquidity and leverage profile for a specialty chemical and materials manufacturer, with modest goodwill exposure and robust interest coverage. Its annualized 8.0% ROE is adequate but below the higher-return threshold, reflecting moderate asset turnover and conservative leverage. Earnings momentum is currently strongest in electronic and medical/piezoelectric materials, while the lower-margin Functional Materials business and extended cash conversion cycle temper the quality of the overall profile.